Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
minimal residual disease
Pharma
BMS is augmenting Zenbexus' efficacy profile in multiple myeloma
BMS has put up the progression-free survival numbers on its recently-approved Zenbexus, more than doubling the score over a control cocktail of DVd.
Fraiser Kansteiner
Oct 8, 2026 2:25pm
BMS bags first FDA approval for CELMoD franchise with Zenbexus
Aug 14, 2026 10:09am
Breakthroughs Honorees
Sep 9, 2024 5:01am
FDA review bodes well for MRD-based myeloma approvals
Apr 10, 2024 11:30am
FDA weighs another approvable myeloma endpoint. What's at stake?
Apr 9, 2024 9:00am
